Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition.
- 1 November 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 90 (5) , 2457-2467
- https://doi.org/10.1161/01.cir.90.5.2457
Abstract
BACKGROUND: Chronic treatment with high doses of angiotensin-converting enzyme (ACE) inhibitors prolongs survival after myocardial infarction. Since the plasma renin-angiotensin system (RAS) is not consistently activated in the chronic phase after myocardial infarction, the beneficial effects of ACE inhibition have been attributed, in part, to inhibition of an activated tissue RAS. However, a relation between tissue ACE inhibition and long-term efficacy (ie, concerning left ventricular [LV] hypertrophy and survival) has not been established. The present study was designed to evaluate the impact of low-dose ACE inhibition (predominant inhibition of plasma ACE) and high-dose ACE inhibition associated with substantial tissue ACE inhibition) on reversal of LV hypertrophy and 1-year mortality after myocardial infarction in the rat. METHODS AND RESULTS: Infarcted rats were randomized to placebo, low-dose lisinopril, or high-dose lisinopril (each, n = 80) and compared with sham-operated animals (n = 40). In a separate group of animals, tissue ACE activity was determined after 6 weeks of therapy, demonstrating that both regimens were effective with regard to both plasma and pulmonary ACE inhibition; however, only high-dose lisinopril inhibited renal ACE. Neither dose affected LV ACE activity and ACE mRNA levels as determined by competitive polymerase chain reaction, whereas LV ANF mRNA levels were significantly reduced by high-dose lisinopril. High-dose lisinopril reduced arterial blood pressure and normalized right ventricular and LV weight and resulted in a substantial reduction of 1-year mortality, whereas the low dose did not (1 year mortality: placebo, 56.3%; low dose, 53.3%; high dose, 22.9%, P < .0001 versus low dose and versus placebo). CONCLUSIONS: Hemodynamically effective ACE inhibition is required for reduction of LV hypertrophy and long-term mortality after myocardial infarction in the rat. Sustained inhibition of renal ACE during long-term therapy may contribute to the beneficial effect of high-dose lisinopril. Low-dose lisinopril, although exerting sustained inhibition of the plasma ACE, does not improve survival after myocardial infarction.Keywords
This publication has 27 references indexed in Scilit:
- Selective Activation of Cardiac Angiotensinogen Gene Expression in Post-infarction Ventricular Remodeling in the RatJournal of Molecular and Cellular Cardiology, 1993
- Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosagesEuropean Heart Journal, 1993
- Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure.Journal of Clinical Investigation, 1992
- Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibitionThe American Journal of Cardiology, 1991
- Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.Journal of Clinical Investigation, 1990
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Picrosirius Red Staining of Cardiac Muscle Following Phosphomolybdic Acid TreatmentStain Technology, 1987
- Multiple simultaneous determinations of hemodynamics and flow distribution in conscious ratJournal of Pharmacological Methods, 1984
- Number and evolutionary conservation of α- and β-tubulin and cytoplasmic β- and γ-actin genes using specific cloned cDNA probesCell, 1980
- Long-Term Preservation of Ischemic Myocardium after Experimental Coronary Artery OcclusionJournal of Clinical Investigation, 1978